Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price traded down 11.1% during mid-day trading on Monday . The company traded as low as C$0.15 and last traded at C$0.16. 16,232,833 shares traded hands during trading, an increase of 1,789% from the average session volume of 859,337 shares. The stock had previously closed at C$0.18.
Hemostemix Stock Down 13.9 %
The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07. The business has a 50-day simple moving average of C$0.21 and a 200-day simple moving average of C$0.12. The stock has a market cap of C$22.59 million, a P/E ratio of -4.52 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- What Are the U.K. Market Holidays? How to Invest and Trade
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
